Diaz-Beya, MarinaBrunet, SNomdedeu, JCordeiro, AnnaTormo, MEscoda, LourdesRibera, J. MArnan, MHeras, InmaculadaGallardo, DavidBargay Lleonart, JoanQueipo de Llano, Maria PazSalamero, OMarti, J. MSampol Mayol, AntoniaPedro, CHoyos, MPratcorona, MCastellano, JJNomdedeu, MRisueno, RMSierra, JMonzo, MNavarro, AEsteve, Jordi2024-07-042024-07-042015-10Diaz-Beya M, Brunet S, Nomdedeu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015 Oct;5:e352.2044-5385http://hdl.handle.net/20.500.13003/10668http://hdl.handle.net/20.500.12105/20149Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.enghttp://creativecommons.org/licenses/by/4.0/Disease-Free SurvivalAgedKaplan-Meier EstimateYoung AdultAdultLeukemia, Myeloid, AcuteHumansAdolescentCytogenetic AnalysisMiddle AgedPrognosisTranscriptomeMaleMicroRNAsNeoplasm ProteinsBiomarkers, TumorFemaleRisk FactorsProportional Hazards Modelsresearch articleAttribution 4.0 International264307235e35210.1038/bcj.2015.76Blood Cancer Journalopen accessModelos de Riesgos ProporcionalesAnálisis CitogenéticoFemeninoBiomarcadores de TumorAdolescenteMasculinoProteínas de NeoplasiasFactores de RiesgoHumanosPersona de Mediana EdadAdulto JovenEstimación de Kaplan-MeierPronósticoAncianoAdultoLeucemia Mieloide AgudaSupervivencia sin EnfermedadMicroARNsTranscriptoma2-s2.0-84943169416368920300002L606212831